De S, Ehrlich M
Genes (Basel). 2024; 15(9).
PMID: 39336785
PMC: 11431212.
DOI: 10.3390/genes15091193.
Mooradian M, Fintelmann F, LaSalle T, Simon J, Graur A, Muzikansky A
Nat Commun. 2024; 15(1):7357.
PMID: 39191779
PMC: 11349953.
DOI: 10.1038/s41467-024-51722-x.
Ying X, You G, Shao R
Transl Cancer Res. 2024; 13(5):2408-2418.
PMID: 38881915
PMC: 11170538.
DOI: 10.21037/tcr-23-2232.
Bhatt D, Meuleman S, Hoogeboom B, Daemen T
iScience. 2024; 27(3):109253.
PMID: 38425844
PMC: 10904282.
DOI: 10.1016/j.isci.2024.109253.
Azumi Y, Koma Y, Tsukamoto S, Kitamura Y, Ishihara N, Yamanaka K
Cells. 2023; 12(22).
PMID: 37998338
PMC: 10670642.
DOI: 10.3390/cells12222603.
Immunotherapy in Melanoma: Recent Advancements and Future Directions.
Mooradian M, Sullivan R
Cancers (Basel). 2023; 15(16).
PMID: 37627204
PMC: 10452647.
DOI: 10.3390/cancers15164176.
Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.
Alshaebi F, Safi M, Algabri Y, Al-Azab M, Aldanakh A, Alradhi M
Front Oncol. 2023; 13:1099696.
PMID: 36798830
PMC: 9927403.
DOI: 10.3389/fonc.2023.1099696.
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.
Xiong F, Wang Q, Wu G, Liu W, Wang B, Chen Y
Biomark Res. 2022; 10(1):69.
PMID: 36104718
PMC: 9472737.
DOI: 10.1186/s40364-022-00415-y.
Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.
Kavanagh M, Horning B, Khattri R, Roy N, Lu J, Whitby L
Nat Chem Biol. 2022; 18(12):1388-1398.
PMID: 36097295
PMC: 7614775.
DOI: 10.1038/s41589-022-01098-0.
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy.
Fujiwara Y, Mittra A, Naqash A, Takebe N
Cancer Drug Resist. 2022; 3(3):252-275.
PMID: 35582437
PMC: 8992481.
DOI: 10.20517/cdr.2020.11.
Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D, Wells A, Clark A
Sci Rep. 2022; 12(1):6657.
PMID: 35459800
PMC: 9033763.
DOI: 10.1038/s41598-022-10724-9.
Role of Hypoxia in the Interferon Response.
Arnaiz E, Harris A
Front Immunol. 2022; 13:821816.
PMID: 35251003
PMC: 8895238.
DOI: 10.3389/fimmu.2022.821816.
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity.
Anderson T, Wooster A, Piersall S, Okpalanwaka I, Lowe D
Semin Cancer Biol. 2022; 86(Pt 3):981-996.
PMID: 35149179
PMC: 9357867.
DOI: 10.1016/j.semcancer.2022.02.009.
Development of Personalized Signature Based on the Immune Landscape to Predict the Prognosis of Osteosarcoma and the Response to Immunotherapy and Targeted Therapy.
Feng X, Zhao Z, Zhao Y, Song Z, Ma Y, Wang W
Front Mol Biosci. 2022; 8:783915.
PMID: 35127816
PMC: 8811188.
DOI: 10.3389/fmolb.2021.783915.
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z, Xu Z, Zhang L, Zou Y, Li J, Yan W
Nat Commun. 2022; 13(1):182.
PMID: 35013322
PMC: 8748754.
DOI: 10.1038/s41467-021-27833-0.
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A, Croci S, Bisagni A, Zanetti E, de Biase D, Melli B
Int J Mol Sci. 2021; 22(22).
PMID: 34830209
PMC: 8618001.
DOI: 10.3390/ijms222212330.
Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?.
Trono P, Tocci A, Musella M, Sistigu A, Nistico P
Biology (Basel). 2021; 10(9).
PMID: 34571790
PMC: 8469949.
DOI: 10.3390/biology10090913.
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.
Musella M, Galassi C, Manduca N, Sistigu A
Biology (Basel). 2021; 10(9).
PMID: 34571733
PMC: 8467547.
DOI: 10.3390/biology10090856.
Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy.
Razaghi A, Brusselaers N, Bjornstedt M, Durand-Dubief M
Neoplasia. 2021; 23(10):1059-1068.
PMID: 34555656
PMC: 8458777.
DOI: 10.1016/j.neo.2021.08.004.
Construction of a Promising Tumor-Infiltrating CD8+ T Cells Gene Signature to Improve Prediction of the Prognosis and Immune Response of Uveal Melanoma.
Sun Y, Wu J, Yuan Y, Lu Y, Luo M, Lin L
Front Cell Dev Biol. 2021; 9:673838.
PMID: 34124058
PMC: 8194278.
DOI: 10.3389/fcell.2021.673838.